Health behaviour
What is left 1 year after mostly non-severe COVID-19?
Open access · cc by · source: Europe PMC
Among 120 Wuhan survivors (~87% non-severe) followed a median 314.5 days, sleep problems, dyspnea, fatigue, joint pain, anxiety/depression, and diffusion impairment remained common.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Study at a glance
- Design
- Cohort — Nearly 1-year follow-up of COVID-19 survivors discharged from Wuhan Union west campus and Fangcang shelters
- N
- N=120 · 120 SARS-CoV-2 patients; 104 (86.7%) non-severe; median 314.5 days from diagnosis to follow-up
- Population
- Adults discharged January–April 2020 from Wuhan designated hospital and Fangcang shelters
- Outcome
- Residual symptoms, anxiety/depression, IgG serostatus, lung function/CT, 6MWT, and labs ~1 year after diagnosis
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
What is left 1 year after mostly non-severe COVID-19?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
120 patients; 104 (86.7%) non-severe; mean age 51.6 ± 10.8 years.
The mean age of the study population was 51.6 ± 10.8 years. Of the 120 patients, 104 (86.7%) were cases of non-severe COVID-19.
Median diagnosis-to-follow-up interval was 314.5 (IQR 296–338) days.
the median time between the diagnosis and the follow-up was 314.5 (IQR, 296–338) days.
Key findings
Mean age 51.6. Sleep difficulty, shortness of breath, fatigue, and joint pain were common; ~one-third of non-severe cases still had these. Anxiety 41.7%, depression 37.5%. 18.3% IgG-negative (20.2% non-severe vs 6.3% severe). Diffusion impairment in 26.1% (24.2% of non-severe).
Methodology
Reassessed 120 discharged patients with symptom/QoL/psychology questionnaires plus spirometry, chest CT, 6MWT, blood tests, and IgG ~1 year after diagnosis (Nov 2020–Jan 2021).
Limitations
Single-center 120-person follow-up without uninfected controls cannot estimate population Long COVID incidence or prove lasting organ damage in every non-severe case.
Related papers in this topic
Same topic cluster — not a recommendation engine.